Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 15/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16696073 | 0.89 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10820458 | 0.87 | KMT2A (0.60) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15635741 | 0.85 | KDM4E (0.63) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16696023 | 0.81 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL22836946 | 0.81 | KDM6B (0.58) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3040698 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3236365 | 0.81 | ALDH1A1 (0.58) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL19689691 | 0.80 | KMT2A (0.49) | KDM4EALDH1A1KMT2AGRIK1 | |
| SCHEMBL432775 | 0.80 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL432773 | 0.80 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| CN-101312720-A | 2-aminobenzamide derivative | ASTELLAS PHARMA INC (JP) | 2008-11-26 | — | — | CN | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6201121-B1 | USEFUL AS ALDOSE REDUCTASE INHIBITORS, BY REACTING A DIHALO BENZYL HALIDE WITH A 1-(CARBOXYALKYL),7-HALO-2,4-QUINAZOLINEDIONE IN THE PRESENCE OF WATER CONTAINING SOLVENT; EFFICIENCY; WORKER SAFETY | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2001-03-13 | — | — | US | disclosed |
| EP-0896961-A1 | PROCESS FOR THE PREPARATION OF 3-DIHALOBENZYL-2,4-QUINAZOLINEDIONE DERIVATIVES | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 1999-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | KDM4E 2205/4885ALDH1A1 1210/4885SMN1; SMN2 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.